LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

LogicBio Therapeutics (Nasdaq:LOGC) announced that CEO Fred Chereau will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. ET. A webcast of the presentation can be accessed on the company's investors page and will be available for 30 days.

LogicBio specializes in genetic medicine, focusing on genome editing and gene delivery technologies for rare diseases.

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Monday, January 10, 2022.

A webcast of the presentation will be made available on the Investors section of the Company's website at www.logicbio.com/investors. The webcast replay will be available for approximately 30 days.

About LogicBio Therapeutics 

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

Investor Contacts:   
Stephen Jasper 
Gilmartin Group 
858-525-2047 
stephen@gilmartinir.com 

Media Contacts: 
Adam Daley 
Berry & Company Public Relations 
W:212-253-8881
C: 614-580-2048 
adaley@berrypr.com

View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-the-hc-wainwright-bioconnect-conference-301453489.html

SOURCE LogicBio Therapeutics, Inc.

FAQ

When will LogicBio Therapeutics participate in the H.C. Wainwright Bioconnect Conference?

LogicBio Therapeutics will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

Who is presenting at the H.C. Wainwright Bioconnect Conference for LOGC?

CEO Fred Chereau will present at the H.C. Wainwright Bioconnect Conference for LogicBio Therapeutics (LOGC).

What is the date and time for the on-demand viewing of LogicBio's presentation?

The on-demand viewing of LogicBio's presentation will start on January 10, 2022, at 7:00 a.m. ET.

Where can I find the webcast of LogicBio's conference presentation?

The webcast of LogicBio's presentation will be available on the company's investors page at www.logicbio.com/investors.

How long will the webcast replay of LogicBio's presentation be available?

The webcast replay will be available for approximately 30 days after the presentation.